FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:MSRB3-HMGA2

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: MSRB3-HMGA2
FusionPDB ID: 55426
FusionGDB2.0 ID: 55426
HgeneTgene
Gene symbol

MSRB3

HMGA2

Gene ID

253827

8091

Gene namemethionine sulfoxide reductase B3high mobility group AT-hook 2
SynonymsDFNB74BABL|HMGI-C|HMGIC|LIPO|STQTL9
Cytomap

12q14.3

12q14.3

Type of geneprotein-codingprotein-coding
Descriptionmethionine-R-sulfoxide reductase B3methionine-R-sulfoxide reductase B3, mitochondrialhigh mobility group protein HMGI-CHMGA2/KRT121P fusionhigh-mobility group (nonhistone chromosomal) protein isoform I-C
Modification date2020031320200329
UniProtAcc

Q8IXL7

Main function of 5'-partner protein: FUNCTION: Catalyzes the reduction of free and protein-bound methionine sulfoxide to methionine. Isoform 2 is essential for hearing. {ECO:0000269|PubMed:14699060, ECO:0000269|PubMed:21185009}.

P52926

Main function of 5'-partner protein: FUNCTION: Functions as a transcriptional regulator. Functions in cell cycle regulation through CCNA2. Plays an important role in chromosome condensation during the meiotic G2/M transition of spermatocytes. Plays a role in postnatal myogenesis, is involved in satellite cell activation (By similarity). Positively regulates IGF2 expression through PLAG1 and in a PLAG1-independent manner (PubMed:28796236). {ECO:0000250|UniProtKB:P52927, ECO:0000269|PubMed:14645522, ECO:0000269|PubMed:28796236}.
Ensembl transtripts involved in fusion geneENST idsENST00000308259, ENST00000355192, 
ENST00000535664, ENST00000540804, 
ENST00000538725, 
ENST00000354636, 
ENST00000393578, ENST00000425208, 
ENST00000536545, ENST00000393577, 
ENST00000403681, ENST00000541363, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score7 X 5 X 4=14016 X 12 X 5=960
# samples 715
** MAII scorelog2(7/140*10)=-1
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(15/960*10)=-2.67807190511264
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: MSRB3 [Title/Abstract] AND HMGA2 [Title/Abstract] AND fusion [Title/Abstract]

Fusion of the HMGA2 and C9orf92 genes in myolipoma with t(9;12)(p22;q14) (pmid: 26857357)
Fusion neoantigen context

PubMed: MSRB3 [Title/Abstract] AND HMGA2 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)HMGA2(66232349)-MSRB3(65856934), # samples:2
HMGA2(66232349)-MSRB3(65856935), # samples:2
MSRB3(65762806)-HMGA2(66345162), # samples:1
MSRB3(65762806)-HMGA2(66345163), # samples:1
Anticipated loss of major functional domain due to fusion event.HMGA2-MSRB3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
HMGA2-MSRB3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
MSRB3-HMGA2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
MSRB3-HMGA2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
MSRB3-HMGA2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
MSRB3-HMGA2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
HMGA2-MSRB3 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF.
HMGA2-MSRB3 seems lost the major protein functional domain in Hgene partner, which is a transcription factor due to the frame-shifted ORF.
HMGA2-MSRB3 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.
MSRB3-HMGA2 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
MSRB3-HMGA2 seems lost the major protein functional domain in Tgene partner, which is a CGC due to the frame-shifted ORF.
MSRB3-HMGA2 seems lost the major protein functional domain in Tgene partner, which is a transcription factor due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneMSRB3

GO:0030091

protein repair

14699060

TgeneHMGA2

GO:0000122

negative regulation of transcription by RNA polymerase II

14627817

TgeneHMGA2

GO:0002062

chondrocyte differentiation

21484705

TgeneHMGA2

GO:0006284

base-excision repair

19465398

TgeneHMGA2

GO:0007095

mitotic G2 DNA damage checkpoint

16061642

TgeneHMGA2

GO:0010564

regulation of cell cycle process

14645522

TgeneHMGA2

GO:0010628

positive regulation of gene expression

18832382

TgeneHMGA2

GO:0031052

chromosome breakage

19549901

TgeneHMGA2

GO:0031507

heterochromatin assembly

16901784

TgeneHMGA2

GO:0035978

histone H2A-S139 phosphorylation

16061642

TgeneHMGA2

GO:0035986

senescence-associated heterochromatin focus assembly

16901784

TgeneHMGA2

GO:0035988

chondrocyte proliferation

21484705

TgeneHMGA2

GO:0042769

DNA damage response, detection of DNA damage

19465398

TgeneHMGA2

GO:0043065

positive regulation of apoptotic process

16061642

TgeneHMGA2

GO:0043066

negative regulation of apoptotic process

19465398

TgeneHMGA2

GO:0043392

negative regulation of DNA binding

14645522

TgeneHMGA2

GO:0043922

negative regulation by host of viral transcription

17005673

TgeneHMGA2

GO:0045869

negative regulation of single stranded viral RNA replication via double stranded DNA intermediate

17005673

TgeneHMGA2

GO:0045892

negative regulation of transcription, DNA-templated

18832382

TgeneHMGA2

GO:0045893

positive regulation of transcription, DNA-templated

15225648|15755872|17005673|17324944|17426251

TgeneHMGA2

GO:0045944

positive regulation of transcription by RNA polymerase II

14645522|18832382

TgeneHMGA2

GO:0071158

positive regulation of cell cycle arrest

16061642

TgeneHMGA2

GO:0071902

positive regulation of protein serine/threonine kinase activity

19549901

TgeneHMGA2

GO:0090402

oncogene-induced cell senescence

16901784

TgeneHMGA2

GO:2000648

positive regulation of stem cell proliferation

21484705

TgeneHMGA2

GO:2000679

positive regulation of transcription regulatory region DNA binding

18832382

TgeneHMGA2

GO:2000685

positive regulation of cellular response to X-ray

16061642

TgeneHMGA2

GO:2001022

positive regulation of response to DNA damage stimulus

16061642|19465398

TgeneHMGA2

GO:2001033

negative regulation of double-strand break repair via nonhomologous end joining

19549901

TgeneHMGA2

GO:2001038

regulation of cellular response to drug

16061642



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr12:66232349/chr12:65856934)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across MSRB3 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across HMGA2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000355192MSRB3chr1265762806+ENST00000541363HMGA2chr1266345162+7911439111482123
ENST00000308259MSRB3chr1265762806+ENST00000541363HMGA2chr1266345162+8038566226609127
ENST00000540804MSRB3chr1265762806+ENST00000541363HMGA2chr1266345162+782235022393123
ENST00000535664MSRB3chr1265762806+ENST00000541363HMGA2chr1266345162+8103631291674127
ENST00000355192MSRB3chr1265762806+ENST00000541363HMGA2chr1266345163+7911439111482123
ENST00000308259MSRB3chr1265762806+ENST00000541363HMGA2chr1266345163+8038566226609127
ENST00000540804MSRB3chr1265762806+ENST00000541363HMGA2chr1266345163+782235022393123
ENST00000535664MSRB3chr1265762806+ENST00000541363HMGA2chr1266345163+8103631291674127

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000355192ENST00000541363MSRB3chr1265762806+HMGA2chr1266345162+0.0518656750.9481343
ENST00000308259ENST00000541363MSRB3chr1265762806+HMGA2chr1266345162+0.0223423430.9776577
ENST00000540804ENST00000541363MSRB3chr1265762806+HMGA2chr1266345162+0.050774980.949225
ENST00000535664ENST00000541363MSRB3chr1265762806+HMGA2chr1266345162+0.0221486430.97785133
ENST00000355192ENST00000541363MSRB3chr1265762806+HMGA2chr1266345163+0.0518656750.9481343
ENST00000308259ENST00000541363MSRB3chr1265762806+HMGA2chr1266345163+0.0223423430.9776577
ENST00000540804ENST00000541363MSRB3chr1265762806+HMGA2chr1266345163+0.050774980.949225
ENST00000535664ENST00000541363MSRB3chr1265762806+HMGA2chr1266345163+0.0221486430.97785133

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for MSRB3-HMGA2

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
MSRB3chr1265762806HMGA2chr126634516235099GIYKCVVCGTPLFKSETKFDSGSATT
MSRB3chr1265762806HMGA2chr126634516243999GIYKCVVCGTPLFKSETKFDSGSATT
MSRB3chr1265762806HMGA2chr1266345162566103GIYKCVVCGTPLFKSETKFDSGSATT
MSRB3chr1265762806HMGA2chr1266345162631103GIYKCVVCGTPLFKSETKFDSGSATT
MSRB3chr1265762806HMGA2chr126634516335099GIYKCVVCGTPLFKSETKFDSGSATT
MSRB3chr1265762806HMGA2chr126634516343999GIYKCVVCGTPLFKSETKFDSGSATT
MSRB3chr1265762806HMGA2chr1266345163566103GIYKCVVCGTPLFKSETKFDSGSATT
MSRB3chr1265762806HMGA2chr1266345163631103GIYKCVVCGTPLFKSETKFDSGSATT

Top

Potential FusionNeoAntigen Information of MSRB3-HMGA2 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
MSRB3-HMGA2_65762806_66345162.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
MSRB3-HMGA2chr1265762806chr1266345162566HLA-A30:08VVCGTPLFK0.97520.6945514
MSRB3-HMGA2chr1265762806chr1266345162566HLA-A74:03VVCGTPLFK0.86090.5879514
MSRB3-HMGA2chr1265762806chr1266345162566HLA-A74:11VVCGTPLFK0.86090.5879514
MSRB3-HMGA2chr1265762806chr1266345162566HLA-A74:09VVCGTPLFK0.86090.5879514
MSRB3-HMGA2chr1265762806chr1266345162566HLA-B35:01TPLFKSETKF0.92310.5016919
MSRB3-HMGA2chr1265762806chr1266345162566HLA-B35:08TPLFKSETKF0.91450.6309919
MSRB3-HMGA2chr1265762806chr1266345162566HLA-A30:01VVCGTPLFK0.97290.8387514
MSRB3-HMGA2chr1265762806chr1266345162566HLA-A74:01VVCGTPLFK0.86090.5879514
MSRB3-HMGA2chr1265762806chr1266345162566HLA-B35:23TPLFKSETKF0.92690.5178919
MSRB3-HMGA2chr1265762806chr1266345162566HLA-B35:77TPLFKSETKF0.92310.5016919
MSRB3-HMGA2chr1265762806chr1266345162566HLA-B35:11TPLFKSETKF0.85360.6216919

Top

Potential FusionNeoAntigen Information of MSRB3-HMGA2 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
MSRB3-HMGA2_65762806_66345162.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-0466TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-0466GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-0802TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-0809TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-0813TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-0821TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-0824TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-0824GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1101TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1101GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1105TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1105GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1108TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1108GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1109TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1109GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1110TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1110GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1111TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1112TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1112GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1115TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1115GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1119TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1119GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1124TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1124GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1127TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1127GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1128TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1128GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1129TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1129GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1131TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1131GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1132TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1132GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1133TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1133GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1137TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1137GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1139TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1139GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1145TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1149TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1149GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1151TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1151GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1153TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1153GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1161TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1161GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1162TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1162GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1164TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1166TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1166GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1169TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1169GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1172TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1173TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1173GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1174TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1174GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1175TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1175GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1179TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1179GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1180TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1180GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1181TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1181GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1182TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1182GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1187TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1187GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1190TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1190GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1191TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1191GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1193TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1193GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1194TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1194GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1195TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1195GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1196TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1196GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1305TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1305GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1307TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1307GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1314TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1314GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1326TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1326GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1337TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1337GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1347TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1350TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1350GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1356TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1356GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1360TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1360GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1362TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1362GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1363TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1366TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1382TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1382GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1385TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1385GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1386TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1402TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1402GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1409TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1409GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1413TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1419TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1419GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1422TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1424TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1425TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1427TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1430TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1430GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1441TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1441GTPLFKSETKFDSGS823
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1494TPLFKSETKFDSGSA924
MSRB3-HMGA2chr1265762806chr1266345162566DRB1-1494GTPLFKSETKFDSGS823

Top

Fusion breakpoint peptide structures of MSRB3-HMGA2

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
9818VCGTPLFKSETKFDMSRB3HMGA2chr1265762806chr1266345162566

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of MSRB3-HMGA2

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN9818VCGTPLFKSETKFD-8.55667-8.74867
HLA-B14:023BVN9818VCGTPLFKSETKFD-3.49457-4.25557
HLA-B52:013W399818VCGTPLFKSETKFD-7.26725-7.45925
HLA-B52:013W399818VCGTPLFKSETKFD-4.01461-4.77561
HLA-A24:025HGA9818VCGTPLFKSETKFD-7.65911-8.42011
HLA-A24:025HGA9818VCGTPLFKSETKFD-7.10204-7.29404
HLA-B44:053DX89818VCGTPLFKSETKFD-7.5556-8.3166
HLA-B44:053DX89818VCGTPLFKSETKFD-2.76159-2.95359

Top

Vaccine Design for the FusionNeoAntigens of MSRB3-HMGA2

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
MSRB3-HMGA2chr1265762806chr1266345162514VVCGTPLFKAAACCAAATTTGACTCCGGTTCAGCCA
MSRB3-HMGA2chr1265762806chr1266345162919TPLFKSETKFACTCCGGTTCAGCCACAACAAGTTGTTCAG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
MSRB3-HMGA2chr1265762806chr1266345162823GTPLFKSETKFDSGSTTGACTCCGGTTCAGCCACAACAAGTTGTTCAGAAGAAGCCTGCT
MSRB3-HMGA2chr1265762806chr1266345162924TPLFKSETKFDSGSAACTCCGGTTCAGCCACAACAAGTTGTTCAGAAGAAGCCTGCTCAG

Top

Information of the samples that have these potential fusion neoantigens of MSRB3-HMGA2

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
SARCMSRB3-HMGA2chr1265762806ENST00000308259chr1266345162ENST00000541363TCGA-DX-A7EI

Top

Potential target of CAR-T therapy development for MSRB3-HMGA2

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to MSRB3-HMGA2

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to MSRB3-HMGA2

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
TgeneHMGA2C1519176Salivary Gland Pleomorphic Adenoma2ORPHANET
TgeneHMGA2C0005612Birth Weight1CTD_human
TgeneHMGA2C0006826Malignant Neoplasms1CTD_human
TgeneHMGA2C0027626Neoplasm Invasiveness1CTD_human
TgeneHMGA2C0027651Neoplasms1CTD_human
TgeneHMGA2C0086692Benign Neoplasm1CTD_human
TgeneHMGA2C0175693Russell-Silver syndrome1GENOMICS_ENGLAND
TgeneHMGA2C0473935Radiolabeled somatostatin analog study1GENOMICS_ENGLAND
TgeneHMGA2C0796160MENTAL RETARDATION, X-LINKED, SNYDER-ROBINSON TYPE1GENOMICS_ENGLAND
TgeneHMGA2C1096309Myolipoma1GENOMICS_ENGLAND
TgeneHMGA2C430514012q14 microdeletion syndrome1ORPHANET